Ciramadol. A new analgesic.
Ciramadol (WY 15705), a new analgesic and narcotic antagonist was studied on oral-dose form in 16 patients (15 of whom were suffering from malignant disease) to evaluate the analgesic dose and toxicity. Patients with mild or moderate pain experienced effective relief with doses of from 20 mg to 60 mg (mean dose, 47 mg). In patients with moderate to severe pain, effective pain control was not achieved (mean dose, 82 mg). There was no consistent effect on blood pressure level, heart rate, or respiratory rate. Mild or moderate sedation occurred in eight patients. Nausea and vomiting occurred in two patients.
D000328:Adult; D000368:Aged; D000588:Amines / Q000627:therapeutic use*; D000700:Analgesics / Q000627:therapeutic use*; D001596:Benzylamines / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000627:therapeutic use; D006261:Headache / Q000150:complications; D006801:Humans; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications; D010148:Intractable Pain / Q000188:drug therapy*
D000588:Amines; D000700:Analgesics; D001596:Benzylamines; D003511:Cyclohexanols; C018273:ciramadol